Dihydrofolate reductase (DHFR)
Dihydrofolate reductase (DHFR) catalyzes the reduction of dihydrofolate to tetrahydrofolate using NADPH, and it is involved in the synthesis of nucleotide, in both prokaryotic and eukaryotic cells. DHFR inhibitors are commonly used for fighting malaria and other protozoal infections, as well as for treating fungal, bacterial, and mycobacterial infections.
All Product Categories
-
Dihydrofolate reductase (DHFR) Inhibitors
(84)
View all products
-
Dihydrofolate reductase (DHFR) Agonists
(2)
View all products
-
Dihydrofolate reductase (DHFR) Activators
(2)
View all products
-
Dihydrofolate reductase (DHFR) Degraders
(4)
View all products
-
Dihydrofolate reductase (DHFR) Substrate
(1)
View all products
-
Dihydrofolate reductase (DHFR) Related Products (100)
Related Products (100)
-
Antibodies (2)
-
Chlorasquin
0 ImagesCat. No.: HY-121256CAS No.: 18921-73-8Chlorasquin inhibits thymidylate synthetase with an approximate Ki value of 4.9 μM. Chlorasquin is also a folate antagonist, testing the Methotrexate (HY-14519) effect. Chlorasquin binds tighter to dihydrofolate reductase at alkaline pH than does Methotrexate, which is promising for research of antipsoriatic agents.
-
(±)-Methotrexate-d3
0 ImagesCat. No.: HY-121151SSynonyms: (±)-Amethopterin-d3; (±)-CL14377-d3; (±)-WR19039-d3(±)-Methotrexate-d3 ((±)-Amethopterin-d3; (±)-CL14377-d3; (±)-WR19039-d3) is the deuterated-labeled (±)-Methotrexate (HY-121151). (±)-Methotrexate is the racemate of Methotrexate (HY-14519). Methotrexate is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
-
10-Formylfolic acid (Standard)
0 ImagesCat. No.: HY-124350RCAS No.: 134-05-410-Formylfolic acid (Standard) is the analytical standard of 10-Formylfolic acid (HY-124350). This product is intended for research and analytical applications. 10-Formylfolic acid is a potent inhibitor of dihydrofolate reductase, with an IC50 of 80 nM against the rat enzyme. 10-Formylfolic acid also acts as an orally active folate source and a growth factor for specific bacteria. 10-Formylfolic acid supports growth and increases plasma folate levels; its absorption and metabolism patterns are similar to those of folic acid, but its liver retention is slightly higher. It exhibits high folate activity in microbial assays, serves as a growth factor for Enterococcus faecalis and Lactobacillus casei, aids folate nutrient supply, and may exert cell regulatory functions.
-
MAHS-3
0 ImagesCat. No.: HY-187513MAHS-3 is a thymidylate synthase (TS) and dihydrofolate reductase (DHFR) inhibitor, with IC50 values of 5.279 μM and 52.60 μM against human targets, respectively. MAHS-3 exhibits broad-spectrum antiproliferative activity against cancer cells, induces cell cycle arrest, activates endogenous caspase-dependent apoptosis, reduces MMP levels, inhibits cell migration, increases intracellular NO levels, and promotes autophagy activity. MAHS-3 can be used in cancer-related research.
-
(±)-Methotrexate
0 ImagesCat. No.: HY-121151CAS No.: 60388-53-6Synonyms: (±)-Amethopterin; (±)-CL14377; (±)-WR19039(±)-Methotrexate ((±)-Amethopterin; (±)-CL14377; (±)-WR19039) is the racemate of Methotrexate (HY-14519). Methotrexate is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
-
AR-102
0 ImagesCat. No.: HY-19885CAS No.: 955005-63-7AR-102 has inhibitory activity towards Staphylococcus aureus. AR-102 exhibits a competitive potent inhibition of the F98Y mutant DHFR (Ki = 0.22 nM). AR-102 has been determined as ternary complex with NADPH in both wild-type S. aureus DHFR and the TMP-resistant F98Y mutant enzyme.
-
Talotrexin monoammonium
0 ImagesCat. No.: HY-10824ACAS No.: 648420-92-2Synonyms: PT523 monoammoniumTalotrexin monoammonium is the monoammonium salt form of Talotrexin (HY-10824). Talotrexin monoammonium is an analog of Aminopterin (HY-14518), and is a nonpolyglutamatable classic antifolate. Talotrexin monoammonium is a reduced folate carrier (RFC) specific inhibitor and selectively inhibits RFC transport. Talotrexin monoammonium shows antitumor activity by targeting DHFR to inhibit tumor growth.
-
(±)-Methotrexate-13C,d3 disodium
0 ImagesCat. No.: HY-121151S2Synonyms: (±)-Amethopterin-13C,d3 disodium; (±)-CL14377-13C,d3 disodium; (±)-WR19039-13C,d3 disodium(±)-Methotrexate-13C,d3 disodium ((±)-Amethopterin-13C,d3 disodium; (±)-CL14377-13C,d3 disodium; (±)-WR19039-13C,d3 disodium) is the deuterated, 13C-labeled (±)-Methotrexate (HY-121151). (±)-Methotrexate is the racemate of Methotrexate (HY-14519). Methotrexate is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
-
MAHS-4
0 ImagesCat. No.: HY-187514MAHS-4 is an inhibitor of thymidylate synthase (TS) and dihydrofolate reductase (DHFR), with IC50 values of 1.918 μM and 83.53 μM, respectively. MAHS-4 inhibits thymidylate biosynthesis, reduces tetrahydrofolate pool maintenance, and interferes with extracellular matrix remodeling. MAHS-4 induces G2/M phase cell cycle arrest, activates endogenous caspase-dependent apoptosis, decreases MMP protein levels, inhibits cell migration, increases intracellular NO levels, and promotes autophagy activity. MAHS-4 is applicable for cancer-related research.
-
UCP1173
0 ImagesCat. No.: HY-183053CAS No.: 1922152-09-7UCP1173, propargyl-linked antifolate, is an antibacterial agent. UCP1173 inhibits DHFR enzymes, with IC50 values of 0.014 μM for DfrB, 0.19 μM for DfrG, 0.27 μM for DfrA, and 0.091 μM for DfrK. UCP1173 inhibits growth of Staphylococcus aureus clinical isolates carrying dfrA, dfrG, or dfrK resistance genes. UCP1173 can be used for the research of bacterial infections.
-
Baquiloprim (Standard)
0 ImagesCat. No.: HY-19581RCAS No.: 102280-35-3Baquiloprim (Standard) is the analytical standard of Baquiloprim (HY-19581). This product is intended for research and analytical applications. Baquiloprim is an orally active Antibiotic and selective inhibitor of Bacterial Dihydrofolate reductase (DHFR), with an IC50 of 19 nM against E. coli and an IC50 of 190 μM against rat liver dihydrofolate reductase. Baquiloprim is a bacteriostatic broad-spectrum antibacterial agent that acts against Gram-negative and Gram-positive bacteria. Baquiloprim inhibits glucuronidation in cultured hepatocytes. Baquiloprim can be used in research related to Pasteurella haemolytica infection, bacterial infection, Escherichia coli diarrhea, bacterial infection in pigs, and pneumonic pasteurellosis.
-
DHFR-IN-15
0 ImagesCat. No.: HY-161064CAS No.: 3049475-31-9DHFR-IN-15 (compound 34) is a dihydrofolate reductase (DHFR) inhibitor with potential anticancer activity. DHFR-IN-15 effectively binds to DHFR in cells, reducing DHFR levels to 10 nM.
-
MMV675968
0 ImagesCat. No.: HY-182684CAS No.: 159308-73-3MMV675968 is an inhibitor of Acinetobacter baumannii dihydrofolate reductase (AbDHFR) with an IC50 of 8.5 nM, and it exhibits selectivity against human DHFR. MMV675968 inhibits dihydrofolate reductase in Cryptosporidium, Plasmodium, and Escherichia coli, disrupting the thymidylate cycle and folate biosynthesis pathway. MMV675968 inhibits the growth of multiple A. baumannii strains, including clinical isolates and environmental isolates. MMV675968 is applicable to research related to A. baumannii infections.
-
Mafenide propionate
0 ImagesCat. No.: HY-B0614CCAS No.: 12001-72-8Mafenide propionate is a dual inhibitor of dihydropteroate synthase (Dihydropteroate synthase) and carbonic anhydrase (Carbonic anhydrase). Mafenide propionate disrupts nucleotide biosynthesis by inhibiting the de novo base synthesis pathway, thereby exerting broad-spectrum antibacterial and cytotoxic effects without inducing mutations. Mafenide propionate can be used for wound assessment and promotes the formation of healthy granulation tissue, making it suitable for scenarios such as mesh skin grafting. Mafenide propionate has been widely used in studies on diseases associated with burn wound infections, acute and chronic wounds, blast injuries, open fractures, and necrotizing fasciitis.
-
DHFR-IN-22
0 ImagesCat. No.: HY-159899CAS No.: 2941327-87-1DHFR-IN-22 (Compound 8) is a DHFR (Dihydrofolate Reductase) inhibitor belonging to the class of 2,4-diaminopyrimidine compounds. DHFR-IN-22 exhibits significant inhibitory activity against purified DHFR enzyme and major species of nontuberculous mycobacteria (NTM), namely Mycobacterium avium and Mycobacterium abscessus. It shows an IC50 of 1.1 nM and MIC of 1.5 μg/mL against M. abscessus, and an IC50 of 6.3 nM and MIC of 0.1 μg/mL against M. avium. Additionally, it demonstrates an IC50 of 2100 nM against human DHFR. DHFR-IN-22 holds potential for studying novel strategies to combat NTM infections.
-
DHFR-IN-13
0 ImagesCat. No.: HY-161010DHFR-IN-13 (Compd Hit8) is an active R. solani DHFR inhibitor with an IC50 value of 10.2 μM. DHFR-IN-13 has selectivity of inhibition against human DHFR with an IC50 value of 227.7 μM. DHFR-IN-13 also is a fungicide. DHFR-IN-13 has high antifungal activity against R. solani with EC50 value of 38.2 mg/L.
-
10-Deazaaminopterin
0 ImagesCat. No.: HY-125647CAS No.: 52454-37-210-Deazaaminopterin is a potent inhibitor of dihydrofolate reductase. 10-Deazaaminopterin can used in study advanced cancer.
-
DHFR-IN-28
0 ImagesCat. No.: HY-W167448CAS No.: 1931-17-5DHFR-IN-28 is an inhibitor of Plasmodium falciparum dihydrofolate reductase (DHFR), with a Ki value of 20.0 nM against wild-type pfDHFR. DHFR-IN-28 inhibits the growth of both wild-type and A16V+S108T mutant Plasmodium falciparum. DHFR-IN-28 is applicable for research related to malaria.
-
DHFR-IN-20
0 ImagesCat. No.: HY-168069DHFR-IN-20 (Compound LA1) is a Plasmodium falciparum dihydrofolate reductase (DHFR) inhibitor, with Kis of 0.16, 0.30, 6.6 nM for PfDHFR-WT, PfDHFR-QM, HsDHFR. DHFR-IN-20 has antimalarial activities (IC50: 1.4 nM and 1.6 μM for P. falciparum carrying the wild-type (TM4/8.2) and the quadruple mutant (V1/S) PfDHFR enzyme.
-
Methasquin
0 ImagesCat. No.: HY-187636CAS No.: 18921-70-5Methasquin is an antifolate dihydrofolate reductase inhibitor (antifolate dihydrofolate reductase) with an IC50 of 1.3 nM against dihydrofolate reductase derived from human leukemia cells. Methasquin binds to dihydrofolate reductase, depletes tetrahydrofolate derivatives, disrupts thymidylate synthesis and inhibits DNA synthesis. Methasquin can be used in leukemia-related research.
